# Dicerna Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dicerna-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.dicerna.com
- Total disclosed funding: $105M
- Latest round: Series C (Aug 1, 2013)
- Investors on record: 9

## About

Dicerna Pharmaceuticals, Inc. is a biotechnology company that specializes in developing innovative RNAi-based therapies to treat rare genetic diseases and cancer, focusing on improving patient outcomes through targeted therapies.Dicerna Pharmaceuticals, Inc. was founded in 2007 and is based in Lexington, US. The company is engaged in the development of RNA interference (RNAi) therapies, which aim to silence genes associated with various diseases. In 2014, Dicerna raised USD 90 mn in an IPO, selling 6 million shares at USD 15 per share on the NASDAQ. The company has completed a total of 8 deals to date, with the most recent deal occurring on January 29, 2014. Dicerna has also raised a total of USD 330 mn with its latest funding round being a Trade Sale involving Novo Nordisk A/S.Dicerna Pharmaceuticals focuses on developing RNA interference (RNAi) therapies that target specific genes involved in disease processes. Their innovative approach is designed to provide precise treatments for conditions such as rare genetic diseases and various forms of cancer. The company's pipeline includes multiple drug candidates aimed at silencing disease-causing genes, with the potential to improve therapeutic outcomes and enhance patient quality of life.In the most recent fiscal year of 2020, Dicerna Pharmaceuticals generated revenue of USD 164.31 mn, while reporting an EBITDA of USD -110.62 mn for the same year.Dicerna Pharmaceuticals plans to utilize its recent funding to advance the development of its RNAi-based therapies and expand its product pipeline. The company is focused on launching new products targeting rare genetic disorders and cancer therapies in the coming years. Additionally, Dicerna is aiming to expand its market reach, particularly in North America and Europe, by leveraging partnerships and collaborations with healthcare providers. The funds from the recent Trade Sale will support these initiatives, enabling Dicerna to enhance its research capabilities and accelerate product development.

## Funding rounds

- Series C, Aug 1, 2013, $60M — Abingworth, Domain Associates, Oxford Bioscience Partners, Skyline Ventures, Brookside Capital Partners, SR One, Deerfield Capital Management, Omega Funds, RA Capital Management
- Series B, Aug 5, 2010, $25M — Abingworth, Domain Associates, Oxford Bioscience Partners, Skyline Ventures
- Series A, Jul 15, 2008, $8.4M — Abingworth, Oxford Bioscience Partners, Skyline Ventures
- Series A, Nov 14, 2007, $12M — Oxford Bioscience Partners, Skyline Ventures

## Investors

- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series A, Series B, Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B, Series C
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B, Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C
- Brookside Capital Partners (https://capitalatlas.ai/funds/brookside-capital-partners) — Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- Deerfield Capital Management (https://capitalatlas.ai/funds/deerfield-capital-management) — Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C